According to the Australian Journal of General Practice, published by the Royal Australian College of General Practitioners, more than 130,000 medicinal cannabis approvals have been issued in Australia to date, mostly by general practitioners, with approximately 65% of these to treat chronic non-cancer pain. Despite robust supportive data from animal models, current clinical trial evidence for THC and CBD efficacy in chronic pain is incomplete. In their prescribing decisions, doctors must balance patient demand and curiosity with caution regarding potential risks and limited efficacy (Source: https://www1.racgp.org.au/ajgp/2021/october/medicinal-cannabis)
Australian Health Journal met with 3 speakers at the recent @arcsaustralia ARCS22 Conference providing an update on medicinal cannabis. The discussion with the speakers now centres on affordability and access.
You Might also like
-
Sharing the same goals in value-based procurement
Value-based procurement (VBP) is a journey, not a sprint. It’s about putting the patient at the centre of quality affordable healthcare through changes in procurement practices for medical technologies. Patient outcomes drive value and sustainability, not just price. The bigger picture indicates that VBP will create system cost saving through benefitting patients, rather than trying to attain the reverse – a win-win outcome.
-
Addressing Wound Management
The cost of chronic wounds in Australia is estimated to be $3 Billion per year, impacting 420,000 Australians. Not only is this a national economic concern, but more importantly, is the suffering the person may be going through.
Australian Health Journal met with Hayley Ryan, Board Director and Chair at Wounds Australia and Director at WoundRescue to hear her work in chronic wound management, palliative wounds and pressure injury prevention to comfort those living with a wound.
-
Clinical Trials in Australia
Shanny Dyer, CEO ARCS Australia talks about a recent summit where the CRO (Contract Research Organization) community was asked on the current state of clinical trials in Australia.